# US 2008/0260762 A1 · HLA binding motifs and peptides and their uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0260762 A1
- Document ID: US20080260762A1
- Status: Published application
- Kind: A1
- Application number: 11/978,519
- Filed: 2007-10-30
- Published: 2008-10-23
- Earliest claimed: 1992-08-07
- Inventors: Howard M. Grey; Alessandro Sette; John Sidney; Scott Southwood; Ralph T. Kubo; Esteban Celis; Robert Chesnut; W. Martin Kast
- Web page: https://patentgrep.com/patent/US20080260762A1

## CPC

- C07K 7/06: having 5 to 11 amino acids
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 39/0011: {Cancer antigens}
- A61K 39/02: Bacterial antigens
- A61K 39/12: Viral antigens
- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/5158: {Antigen-pulsed cells, e.g. T-cells}
- A61K 2039/55516: {Proteins; Peptides}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/572: {cytotoxic response}
- C07K 2319/01: containing a localisation/targetting motif
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K 2319/40: containing a tag for immunodetection, or an epitope for immunisation
- C12N 2710/00088: for redistribution
- C12N 2710/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2730/10134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/24234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles and inducing T cell activation in T cells restricted by the allele. The peptides are useful to elicit an immune response against a desired antigen.

## Claims

### Claim 1

(canceled)

### Claim 2

A peptide selected from the group consisting of peptides found in Tables 2-189.

### Claim 3

An isolated peptide less than 15 amino acids in length comprising the oligopeptide LLTFWNPPV (SEQ ID NO:11419).

### Claim 4 (depends on 3)

A composition comprising the peptide of claim 3, wherein said peptide is linked to a T helper peptide.

### Claim 5 (depends on 3)

A composition comprising the peptide of claim 3, wherein said peptide is linked to a spacer or linker, wherein said spacer or linker is between one and six amino acids in length.

### Claim 6 (depends on 3)

A composition comprising the peptide of claim 3, wherein said peptide is linked to a carrier.

### Claim 7 (depends on 3)

A composition comprising the peptide of claim 3, wherein said peptide is linked to a lipid.

### Claim 8 (depends on 4)

A composition comprising the peptide of claim 4, wherein said T-helper peptide is the PADRE helper peptide having the sequence aKXVAAWTLKAAa (SEQ ID NO:14635), wherein a is d-alanine and X is cyclohexylalanine.

### Claim 9 (depends on 3)

A homopolymer of the peptide of claim 3.

### Claim 10 (depends on 3)

A heteropolymer of the peptide of claim 3 and at least one different peptide, wherein said at least one different peptide is not derived from influenza and is a cytotoxic T cell (CTL)-inducing peptide or a helper T cell (HTL)-inducing peptide.

### Claim 11 (depends on 3)

A composition comprising the peptide of claim 3 and a carrier.

### Claim 12 (depends on 3)

A composition comprising the peptide of claim 3 and a pharmaceutically acceptable excipient.

### Claim 13 (depends on 3)

A composition comprising the peptide of claim 3 and a liposome.

### Claim 14 (depends on 3)

A composition comprising the peptide of claim 3, and one or more different isolated peptides, wherein said one or more different isolated peptides is selected from the group consisting of: a cytotoxic T cell (CTL)-inducing peptide and a helper T cell (HTL)-inducing peptide.

### Claim 15 (depends on 14)

The composition of claim 14, further comprising a carrier.

### Claim 16 (depends on 14)

The composition of claim 14 further comprising a pharmaceutically acceptable excipient.
